Cowen set a $225.00 price objective on Shire (NASDAQ:SHPG) in a research report released on Friday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued reports about the stock. ValuEngine raised shares of Shire from a hold rating to a buy rating in a research report on Thursday, October 26th. Stifel Nicolaus reissued a buy rating and set a $245.00 target price on shares of Shire in a research report on Sunday, October 8th. Royal Bank of Canada reissued a buy rating and set a $213.00 target price on shares of Shire in a research report on Monday, October 2nd. Cantor Fitzgerald reissued a buy rating and set a $222.00 target price on shares of Shire in a research report on Thursday, September 14th. Finally, FBR & Co initiated coverage on shares of Shire in a research report on Thursday, October 19th. They set a buy rating and a $201.00 target price for the company. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have assigned a buy rating to the company’s stock. Shire has an average rating of Hold and an average target price of $212.18.

Shares of Shire (SHPG) opened at $156.86 on Friday. Shire has a 52-week low of $137.17 and a 52-week high of $192.15. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.98 and a quick ratio of 0.52. The stock has a market cap of $47,303.71, a PE ratio of 29.37, a price-to-earnings-growth ratio of 0.85 and a beta of 1.60.

Shire (NASDAQ:SHPG) last issued its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.64 by $0.17. Shire had a net margin of 10.95% and a return on equity of 14.41%. The business had revenue of $3.70 billion during the quarter. During the same period in the previous year, the company posted $3.17 earnings per share. The company’s revenue for the quarter was up 7.1% on a year-over-year basis. equities analysts predict that Shire will post 15 earnings per share for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in SHPG. Harding Loevner LP lifted its stake in shares of Shire by 18,894.4% during the 3rd quarter. Harding Loevner LP now owns 127,537,052 shares of the biopharmaceutical company’s stock valued at $20,354,000 after buying an additional 126,865,607 shares in the last quarter. Janus Henderson Group PLC lifted its stake in shares of Shire by 22,560.3% during the 2nd quarter. Janus Henderson Group PLC now owns 1,286,881 shares of the biopharmaceutical company’s stock valued at $212,683,000 after buying an additional 1,281,202 shares in the last quarter. Third Point LLC purchased a new stake in shares of Shire during the 3rd quarter valued at approximately $183,768,000. Glenview Capital Management LLC lifted its stake in shares of Shire by 69.7% during the 2nd quarter. Glenview Capital Management LLC now owns 1,722,977 shares of the biopharmaceutical company’s stock valued at $284,756,000 after buying an additional 707,500 shares in the last quarter. Finally, Sterling Capital Management LLC lifted its stake in shares of Shire by 26,182.4% during the 3rd quarter. Sterling Capital Management LLC now owns 474,397 shares of the biopharmaceutical company’s stock valued at $72,649,000 after buying an additional 472,592 shares in the last quarter. 20.19% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.dailypolitical.com/2018/01/06/shire-shpg-given-a-225-00-price-target-by-cowen-analysts.html.

About Shire

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Analyst Recommendations for Shire (NASDAQ:SHPG)

Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.